Search fresh public links, source activity, and ready-to-use post angles for Cns Spectrums.
Fresh curated links around CNS Spectrums are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
A new study introduces XL20, an experimental small-molecule drug that crosses the blood-brain barrier to selectively block a toxic region on the TDP-43 protein. This precise mechan...
We talked about effects of CD20 on CNS cells. The paper today helps support the view of the event in the brain as it relates to cladribine. It shows that cladribine is getting MS u...
Kesimpta (ofatumumab) was more effective than Aubagio (teriflunomide) at suppressing disease activity in people with highly active, relapsing forms of multiple sclerosis (MS), acco...
By Dr. Forest Tennant and Ingrid HollisIn 1981, some neuroscience researchers discovered a group of hormones being made in the brain and spinal cord. Some are also made in the gon...
Spero Therapeutics enters immunology with an antibody licensed from Innovent Biologics. The lead indication is a rare autoimmune condition where Spero aims to offer advantages over...
This morning, Compass Pathways shared 26-week data from its second Phase 3 study of COMP360 psilocybin for treatment-resistant depression (TRD). The data are from Part B of COMP006...
On Monday, Definium Therapeutics announced topline data from a Phase 3 trial of its LSD candidate (DT120) for major depressive disorder (MDD). Reaction to the topline has been broa...
Momentum Amidst Tumult: The FDA Reshuffle, Approval Timelines, and the Compass-Usona Race Last week, I (the Editor, Josh Hardman) returned from a trip to the U.S. West Coast, visit...
Pharma platform company China Medical System Holdings has tapped up existing partner Insilico for a 1.2 billion yuan ($177 million) collaboration aimed at a “mass-market” central n...
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
In a wide-ranging interview, Abe Ceesay detailed how Rapport built an investor syndicate and why the company is confident it can join the ranks of successful, commercial-stage brai...
A Closer Look at Compass’ 6-Month Data and Commercial Plans On Tuesday, we covered Compass Pathways’ readout covering 26-week data from its second Phase 3 study of COMP360 psilocyb...
The FDA now treats continuous, real-time data sharing as a regulatory direction of travel rather than a theoretical future. The neurology field should pay close attention. The pos...
In a groundbreaking pediatric prospective cohort study set to reshape emergency neurological care, researchers Seker Gezici, M., Turan, C., and Ayyildiz Emecen, D. have illuminated...
Find out about some early-stage technologies in neurology that aim to go beyond amyloid, dopamine, and what has dominated the field. The post Beyond amyloid and dopamine: emerging...
Bristol Myers' neuroscience heads are trying to make a name in brain drugs for a company best known for its cancer and cell therapy work.
by Arnab Dey Sarkar, Bard Ermentrout In the classical view of cortical rhythms, interactions between excitatory pyramidal neurons (E) and inhibitory parvalbumin-expressing interne...
A new method screens large libraries of synthetic cyclic peptides to identify compounds that can enter cells for therapeutic effect, opening avenues for a modality that combines th...
Immunovant shares climbed on results an analyst deemed “compelling” in tough-to-treat arthritis. Elsewhere, Wave’s pioneering rare disease program advanced and Takeda lost an antit...
Biogen's leading tau-targeting candidate has slowed cognitive decline across a suite of different clinical assessments, backing up the pharma’s decision to race the molecule into p...
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.